U.S. drugmaker Merck & Co (NYS:MRK) plans to resume
sales of the controversial Zilmax animal feed additive in the United States and
Canada after it completes an audit of how the product is used, a spokeswoman
said on Tuesday.
Merck halted sales of the muscle-building drug in August
after Tyson Foods Inc. (NYS:TSN) said it would stop accepting Zilmax-fed beef
given some cattle were observed arriving for slaughter with signs they were
having difficulty walking or moving. Merck has said it stands behind the safety
of its product, but the pause added to global concerns over its use.
On Tuesday, a spokeswoman for Merck's Animal Health unit
said that while "it is too early to speculate on when we will resume sales
for Zilmax in the U.S. and Canada," Merck was pushing forward with its
quality control program to ensure the drug was being properly used. Read more.
No comments:
Post a Comment